Skip to content

Effect of Exercise on Genes That Control Muscle Function

Epigenomic Remodeling of Metabolism by Exercise

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03414385
Enrollment
16
Registered
2018-01-29
Start date
2018-02-01
Completion date
2022-05-31
Last updated
2023-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The proposed project will examine how exercise counteracts metabolic disorders and type 2 diabetes through regulating gene expression. The project is highly relevant to public health because of the global pandemic of diabetes, obesity, and associated metabolic syndromes as well as the well-known metabolic benefit of physical exercise in correcting these disorders.

Detailed description

Exercise is a first-line treatment for type 2 diabetes, and exerts its beneficial effects not only by burning off energy but also by causing prolonged metabolic changes through changing gene expression. Genes are our genetic materials and the expression of genes determines our biology. In our previous study in animals, we identified some factors that drive exercise-induced gene expression changes. Here we would like to address whether the result is also true in human. This work will provide molecular insights into how exercise remodels our metabolism and will potentially find a way to maximize the benefit we get from physical exercise. The purpose of this study is to determine whether acute exercise activate certain molecular factors in human skeletal muscle. Participants will be asked to undergo an acute bout of aerobic exercise at \ moderate intensity for about 2 hours. Before and after the exercise, the participants will undergo a muscle biopsy. The muscle tissues will be used for total RNA extraction and RT-qPCR analysis of genes that include but are not limited to de facto JunD/AP-1 target genes and will also be analyzed by Jun D Chip-qPCT to assess binding of Jun D on its de facto target genes.

Interventions

OTHERExercise

Acute bout of aerobic exercise at moderate intensity for 2 hours

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
US Department of Veterans Affairs
CollaboratorFED
Baylor College of Medicine
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 20 - 40 years * BMI 18.5 - 29.9 * Stable body weight (not more than 2 kg change) during the past 6 months * Moderate sedentary (regular exercise less than 1 hour per week for the last 6 months) * Willing to provide informed consent

Exclusion criteria

* Failure to provide informed consent * Any major chronic disease or any condition that would interfere with exercise, in which exercise is contraindicated, or that would interfere with interpretation of results * Severe orthopedic and or neuromuscular disease that would contraindicate participation in exercise * Other significant co-morbid disease that would impair ability to exercise * Uncontrolled hypertension (BP greater than 160/90) * History of malignancy during the past 5 years * Diabetes mellitus as determined by self-report with verification (medical records, current treatment, confirmation from health care provider), or HbA1c of exceeding 6.5%

Design outcomes

Primary

MeasureTime frameDescription
Change in JunD/AP-1 signaling in human skeletal muscleImmediately after about 2 hours exerciseJunD/AP-target genes

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026